Syros Pharmaceuticals (NASDAQ: SYRS) reported Q3 EPS of ($0.16), $0.52 better than the analyst estimate of ($0.68).

Cash and Financial Guidance

Cash and cash equivalents as of September 30, 2024, were $58.3 million, as compared with $79.0 million as of June 30, 2024.

Based on its current plans, Syros believes that its existing cash and cash equivalents will be sufficient to fund its anticipated operating expenses and capital expenditure requirements into the third quarter of 2025.

For earnings history and earnings-related data on Syros Pharmaceuticals (SYRS) click here.